FDA Eyes Changes To IRB Adverse Event Reporting; March Meeting Planned
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers and other stakeholders will have an opportunity next month to discuss ways that reporting adverse events to institutional review boards can be improved
You may also be interested in...
Adverse Event Reporting Deluge Diagnosed By IRB Reps At FDA Hearing
Clinical trial sponsors should assume oversight of safety data that currently burden institutional review boards, participants agreed at an FDA public hearing on adverse event (AE) reporting to IRBs
Adverse Event Reporting Deluge Diagnosed By IRB Reps At FDA Hearing
Clinical trial sponsors should assume oversight of safety data that currently burden institutional review boards, participants agreed at an FDA public hearing on adverse event (AE) reporting to IRBs
Risk-Based Approach To Clinical AE Reporting Needed – Medtronic’s Westrum
Clinical trial sponsors are limited in their ability to facilitate compliance with institutional review boards, even though investigators often lack thorough grounding in IRB policies, according to Medtronic Director of Clinical Affairs Barbara Westrum